Home 5 Clinical Diagnostics Insider 5 FDA Watch: Expanded Label Clearance Opens Cologuard to a Younger Market

FDA Watch: Expanded Label Clearance Opens Cologuard to a Younger Market

by | Oct 17, 2019 | Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, FDA-dtet

September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.

Subscribe to Clinical Diagnostics Insider to view

Start a Free Trial for immediate access to this article